Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with walter reed stage 2 human immunodeficiency virus infection: Results of ACTG protocol 042

John A. Bartlett, Cindy Berend, Gina R. Petroni, Janet Ottinger, Douglas Tyler, Carla Pettinelli, Kent J. Weinhold

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Interleukin-2 (IL-2) can increase numbers of absolute CD4 cells in persons infected with the human immunodeficiency virus who are receiving antiretroviral therapy. Twenty-five subjects with >400/mm3 absolute CD4 cells received zidovudine and low-dose intravenous or subcutaneous IL-2 (≤106 U/m2). Absolute CD4 cells increased significantly during IL-2 treatment, and 56% of the subjects achieved a maximal increase of ≤500 cells/mm3. A dose-response relationship favored increasing IL-2 doses, and subcutaneous delivery offered greater increases than intravenous administration. Fifteen subjects had persistent increases of ≤ 100 cells/mm3 6 weeks after IL-2 was discontinued. No changes occurred in delayed-type hypersensitivity or helper T cell responses to recall antigens. Cell-mediated cytotoxicities increased against Daudi cells. IL-2 was well tolerated and only 1 subject required dose reduction. Relatively low-dose IL- 2 delivered by subcutaneous or intravenous routes may provide an important complement to antiretroviral therapy to increase absolute CD4 cells with the potential for less toxicity than with higher IL-2 doses.

Original languageEnglish (US)
Pages (from-to)1170-1173
Number of pages4
JournalJournal of Infectious Diseases
Volume178
Issue number4
StatePublished - 1998
Externally publishedYes

Fingerprint

Wiskott-Aldrich Syndrome
Zidovudine
Virus Diseases
Interleukin-2
Delayed Hypersensitivity
Helper-Inducer T-Lymphocytes
Intravenous Administration
Therapeutics
HIV
Antigens

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with walter reed stage 2 human immunodeficiency virus infection : Results of ACTG protocol 042. / Bartlett, John A.; Berend, Cindy; Petroni, Gina R.; Ottinger, Janet; Tyler, Douglas; Pettinelli, Carla; Weinhold, Kent J.

In: Journal of Infectious Diseases, Vol. 178, No. 4, 1998, p. 1170-1173.

Research output: Contribution to journalArticle

Bartlett, John A. ; Berend, Cindy ; Petroni, Gina R. ; Ottinger, Janet ; Tyler, Douglas ; Pettinelli, Carla ; Weinhold, Kent J. / Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with walter reed stage 2 human immunodeficiency virus infection : Results of ACTG protocol 042. In: Journal of Infectious Diseases. 1998 ; Vol. 178, No. 4. pp. 1170-1173.
@article{acce44ce56b942a2a3903cc13e76d595,
title = "Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with walter reed stage 2 human immunodeficiency virus infection: Results of ACTG protocol 042",
abstract = "Interleukin-2 (IL-2) can increase numbers of absolute CD4 cells in persons infected with the human immunodeficiency virus who are receiving antiretroviral therapy. Twenty-five subjects with >400/mm3 absolute CD4 cells received zidovudine and low-dose intravenous or subcutaneous IL-2 (≤106 U/m2). Absolute CD4 cells increased significantly during IL-2 treatment, and 56{\%} of the subjects achieved a maximal increase of ≤500 cells/mm3. A dose-response relationship favored increasing IL-2 doses, and subcutaneous delivery offered greater increases than intravenous administration. Fifteen subjects had persistent increases of ≤ 100 cells/mm3 6 weeks after IL-2 was discontinued. No changes occurred in delayed-type hypersensitivity or helper T cell responses to recall antigens. Cell-mediated cytotoxicities increased against Daudi cells. IL-2 was well tolerated and only 1 subject required dose reduction. Relatively low-dose IL- 2 delivered by subcutaneous or intravenous routes may provide an important complement to antiretroviral therapy to increase absolute CD4 cells with the potential for less toxicity than with higher IL-2 doses.",
author = "Bartlett, {John A.} and Cindy Berend and Petroni, {Gina R.} and Janet Ottinger and Douglas Tyler and Carla Pettinelli and Weinhold, {Kent J.}",
year = "1998",
language = "English (US)",
volume = "178",
pages = "1170--1173",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with walter reed stage 2 human immunodeficiency virus infection

T2 - Results of ACTG protocol 042

AU - Bartlett, John A.

AU - Berend, Cindy

AU - Petroni, Gina R.

AU - Ottinger, Janet

AU - Tyler, Douglas

AU - Pettinelli, Carla

AU - Weinhold, Kent J.

PY - 1998

Y1 - 1998

N2 - Interleukin-2 (IL-2) can increase numbers of absolute CD4 cells in persons infected with the human immunodeficiency virus who are receiving antiretroviral therapy. Twenty-five subjects with >400/mm3 absolute CD4 cells received zidovudine and low-dose intravenous or subcutaneous IL-2 (≤106 U/m2). Absolute CD4 cells increased significantly during IL-2 treatment, and 56% of the subjects achieved a maximal increase of ≤500 cells/mm3. A dose-response relationship favored increasing IL-2 doses, and subcutaneous delivery offered greater increases than intravenous administration. Fifteen subjects had persistent increases of ≤ 100 cells/mm3 6 weeks after IL-2 was discontinued. No changes occurred in delayed-type hypersensitivity or helper T cell responses to recall antigens. Cell-mediated cytotoxicities increased against Daudi cells. IL-2 was well tolerated and only 1 subject required dose reduction. Relatively low-dose IL- 2 delivered by subcutaneous or intravenous routes may provide an important complement to antiretroviral therapy to increase absolute CD4 cells with the potential for less toxicity than with higher IL-2 doses.

AB - Interleukin-2 (IL-2) can increase numbers of absolute CD4 cells in persons infected with the human immunodeficiency virus who are receiving antiretroviral therapy. Twenty-five subjects with >400/mm3 absolute CD4 cells received zidovudine and low-dose intravenous or subcutaneous IL-2 (≤106 U/m2). Absolute CD4 cells increased significantly during IL-2 treatment, and 56% of the subjects achieved a maximal increase of ≤500 cells/mm3. A dose-response relationship favored increasing IL-2 doses, and subcutaneous delivery offered greater increases than intravenous administration. Fifteen subjects had persistent increases of ≤ 100 cells/mm3 6 weeks after IL-2 was discontinued. No changes occurred in delayed-type hypersensitivity or helper T cell responses to recall antigens. Cell-mediated cytotoxicities increased against Daudi cells. IL-2 was well tolerated and only 1 subject required dose reduction. Relatively low-dose IL- 2 delivered by subcutaneous or intravenous routes may provide an important complement to antiretroviral therapy to increase absolute CD4 cells with the potential for less toxicity than with higher IL-2 doses.

UR - http://www.scopus.com/inward/record.url?scp=0031691081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031691081&partnerID=8YFLogxK

M3 - Article

C2 - 9806053

AN - SCOPUS:0031691081

VL - 178

SP - 1170

EP - 1173

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -